세계의 역형성 대세포 림프종 치료제 시장 보고서(2025년)

Anaplastic Large Cell Lymphoma Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

역형성 대세포 림프종 치료제 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 주요 동향으로는 시장에 대한 규제 당국의 지원, 정부의 대처와 자금 원조, 연구 개발 투자 증가, 환자 지원 활동 증가가 있습니다.

표적 치료의 채용 확대가 역형성 대세포 림프종 치료제 시장의 확대를 견인할 것으로 예측됩니다. 임상연구와 기술 혁신의 진전, 암 이환율 증가 등의 요인에 의해 높아지고 있습니다. 강한 조직에의 데미지를 경감해, 전신 독성을 저하시켜, 정밀의료에 의해 환자의 결과를 개선합니다. 예를 들어, 2023년 7월 미국의 전문 회원 단체인 미국 유전자 및 세포 치료학회(ASGCT)와 미국 기반 의약품 및 기기 정보 제공업체인 Citeline이 발표한 보고서에 따르면 임상 2상 시험 중인 유전자 치료제의 수가 2023년 1분기 말 247개에서 2분기 말 260개로 5% 증가했다고 합니다.

역형성 대세포 림프종 치료제 시장의 주요 기업은 치료 효과를 높이고 치료 옵션을 넓히기 위해 임상시험에 투자를 우선하고 있습니다. 임상시험 자금 지원에는 신약, 치료법 또는 의료 기기를 개발, 테스트 및 평가하고 안전성, 효능 및 규제 승인을 보장하기 위해 재정 및 자원을 할당하는 것이 포함됩니다. 예를 들어, 2023년 11월, 미국에 본사를 둔 임상 단계의 세포 치료 회사인 March Biosciences는 재발성 T세포 백혈병 및 림프종 치료를 위한 CD5를 표적으로 하는 새로운 CAR-T 치료제인 MB-105의 임상 2상 시험을 지원하기 위해 Cancer Focus Fund로부터 480만 달러를 투자받았습니다. 림프종 환자를 대상으로 MB-105를 평가합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 역형성 대세포 림프종 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 역형성 대세포 림프종 치료제 시장 : 성장률 분석
• 세계의 역형성 대세포 림프종 치료제 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 역형성 대세포 림프종 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 역형성 대세포 림프종 치료제 전체 시장(TAM)

제6장 시장 세분화

• 세계의 역형성 대세포 림프종 치료제 시장 : 질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 원발성 역형성 대세포 림프종
• 재발성 역형성 대세포 림프종
• 세계의 역형성 대세포 림프종 치료제 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 화학 치료
• 사이클로포스파마이드, 독소루비신, 빈크리스틴 및 프레드니손(CHOP)
• 브렌툭시맙 베도틴
• 프랄라트렉세이트
• 수술
• 방사선 치료
• 줄기세포 이식
• 세계의 역형성 대세포 림프종 치료제 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 입원환자
• 외래환자
• 세계의 역형성 대세포 림프종 치료제 시장 : 원발성 역형성 대세포 림프종 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 피부 타입
• 전신 타입
• 원발성 폐 타입
• 세계의 역형성 대세포 림프종 치료제 시장 : 재발성 역형성 대세포 림프종 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 조기 재발
• 후기 재발

제7장 지역별/국가별 분석

• 세계의 역형성 대세포 림프종 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 역형성 대세포 림프종 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 역형성 대세포 림프종 치료제 시장 : 경쟁 구도
• 역형성 대세포 림프종 치료제 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Fresenius Kabi 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
  • Thermo Fisher Scientific Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis AG
• Takeda Pharmaceutical Company Limited
• Becton, Dickinson and Company
• Teva Pharmaceutical Industries Ltd.
• Genmab A/S
• Seagen Inc.
• Spectrum Pharmaceuticals Inc.
• Kyowa Kirin Co. Ltd.
• Kite Pharma
• MEI Pharma Inc.
• Cell Signaling Technology Inc.
• Acrotech Biopharma Inc.
• Xenothera
• Citius Pharmaceuticals Inc.
• Seattle Genetics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 역형성 대세포 림프종 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 역형성 대세포 림프종 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 역형성 대세포 림프종 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Anaplastic large cell lymphoma (ALCL) therapeutics encompass various treatment strategies designed to manage this rare and aggressive T-cell non-Hodgkin lymphoma (NHL). The primary objective is to eliminate malignant T-cells, achieve remission, and minimize the risk of relapse while reducing adverse effects.

The main disease types for ALCL therapeutics include primary anaplastic large cell lymphoma and relapsed anaplastic large cell lymphoma. Primary ALCL is an aggressive form of non-Hodgkin lymphoma characterized by abnormal T-cell proliferation, often affecting lymph nodes or the skin, and is typically treated with chemotherapy regimens such as CHOP for improved outcomes. Treatment options include chemotherapy, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as well as targeted therapies such as brentuximab vedotin and pralatrexate, along with surgery, radiation therapy, and stem cell transplantation. These therapies are used across various applications, including inpatient and outpatient settings.

The anaplastic large cell lymphoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides anaplastic large cell lymphoma therapeutics market statistics, including the anaplastic large cell lymphoma therapeutics industry global market size, regional shares, competitors with the anaplastic large cell lymphoma therapeutics market share, detailed anaplastic large cell lymphoma therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the anaplastic large cell lymphoma therapeutics industry. This anaplastic large cell lymphoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The anaplastic large cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $10.98 billion in 2024 to $11.72 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to increasing awareness about cancer, the rising incidence of anaplastic large cell lymphoma, advancements in medical research, growing awareness of early diagnosis, and improved adoption of existing treatment options.

The anaplastic large cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $14.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to a greater focus on immuno-oncology, regulatory support for new treatments, government initiatives and funding, rising investments in research and development, and increasing patient advocacy efforts. Major trends include advancements in targeted therapies, the development of novel drug conjugates, a growing emphasis on personalized medicine, increased adoption of combination therapies, and technological advancements in diagnostics.

The increasing adoption of targeted therapies is expected to drive the expansion of the anaplastic large cell lymphoma therapeutics market. Targeted therapies are advanced treatments designed to specifically inhibit molecules or pathways responsible for cancer progression, minimizing harm to healthy cells. The demand for these therapies is rising due to factors such as advancements in precision medicine, growing clinical research and innovations, and the increasing incidence of cancers. In the case of anaplastic large cell lymphoma (ALCL), targeted therapies selectively attack cancer cells with specific molecular alterations, such as ALK gene rearrangements or CD30 expression. This approach enhances treatment efficacy, reduces damage to healthy tissues, lowers systemic toxicity, and improves patient outcomes through precision medicine. For example, in July 2023, a report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drug and device intelligence, indicated that the number of gene therapies in Phase II clinical trials increased from 247 at the end of Q1 2023 to 260 by the end of Q2, reflecting a 5% rise. Consequently, the rising adoption of targeted therapies is contributing to the growth of the anaplastic large cell lymphoma therapeutics market.

Leading companies in the anaplastic large cell lymphoma therapeutics market are prioritizing investments in clinical trials to enhance treatment effectiveness and broaden therapeutic options. Funding clinical trials involves allocating financial and resource commitments to develop, test, and evaluate new drugs, therapies, or medical devices, ensuring their safety, efficacy, and regulatory approval. For instance, in November 2023, March Biosciences, a US-based clinical-stage cell therapy company, secured a $4.8 million investment from the Cancer Focus Fund to support its Phase 2 clinical trial of MB-105, a novel CAR-T therapy targeting CD5 for the treatment of relapsed T-cell leukemias and lymphomas. The open-label, multi-center trial will evaluate MB-105 in patients with CD5-positive relapsed or refractory T-cell lymphoma. March Biosciences anticipates that MB-105 could become a first-in-class, life-saving therapy for relapsed T-cell lymphoma patients who have limited treatment options.

In June 2024, Takeda Pharmaceutical Company, a Japan-based pharmaceutical firm, entered into a partnership with Pfizer Inc. to improve treatment outcomes for lymphoma patients by evaluating ADCETRIS (brentuximab vedotin). Under this collaboration, Pfizer will hold commercialization rights for ADCETRIS in the U.S. and Canada, while Takeda will retain commercialization rights in the rest of the world and manage regulatory filings outside of the U.S. and Canada. Pfizer Inc. is a US-based developer of ADCETRIS (brentuximab vedotin) for the treatment of anaplastic large cell lymphoma.

Major players in the anaplastic large cell lymphoma therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Fresenius Kabi, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Genmab A/S, Seagen Inc., Spectrum Pharmaceuticals Inc., Kyowa Kirin Co. Ltd., Kite Pharma, MEI Pharma Inc., Cell Signaling Technology Inc., Acrotech Biopharma Inc., Xenothera, Citius Pharmaceuticals Inc., Seattle Genetics Inc.

North America was the largest region in the anaplastic large cell lymphoma therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic large cell lymphoma therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anaplastic large cell lymphoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anaplastic large cell lymphoma therapeutics market consists of revenues earned by entities by providing services such as immunotherapy, supportive care and symptom management, personalized treatment planning, post-treatment monitoring, and relapse prevention. The anaplastic large cell lymphoma therapeutics market also includes sales of antibody-drug conjugates and chemotherapy agents. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anaplastic Large Cell Lymphoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anaplastic large cell lymphoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anaplastic large cell lymphoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anaplastic large cell lymphoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Primary Anaplastic Large Cell Lymphoma; Relapsed Anaplastic Large Cell Lymphoma
• 2) By Treatment Type: Chemotherapy; Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone (CHOP); Brentuximab Vedotin; Pralatrexate; Surgery; Radiation Therapy; Stem Cell Transplant
• 3) By Application: In-Patient; Out-Patient
• Subsegments:
• 1) By Primary Anaplastic Large Cell Lymphoma: Cutaneous Type; Systemic Type; Primary Pulmonary Type
• 2) By Relapsed Anaplastic Large Cell Lymphoma: Early Relapse; Late Relapse
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Fresenius Kabi; Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anaplastic Large Cell Lymphoma Therapeutics Market Characteristics

3. Anaplastic Large Cell Lymphoma Therapeutics Market Trends And Strategies

4. Anaplastic Large Cell Lymphoma Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anaplastic Large Cell Lymphoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anaplastic Large Cell Lymphoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anaplastic Large Cell Lymphoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Anaplastic Large Cell Lymphoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anaplastic Large Cell Lymphoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anaplastic Large Cell Lymphoma Therapeutics Total Addressable Market (TAM)

6. Anaplastic Large Cell Lymphoma Therapeutics Market Segmentation

• 6.1. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Anaplastic Large Cell Lymphoma
• Relapsed Anaplastic Large Cell Lymphoma
• 6.2. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone (CHOP)
• Brentuximab Vedotin
• Pralatrexate
• Surgery
• Radiation Therapy
• Stem Cell Transplant
• 6.3. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• In-Patient
• Out-Patient
• 6.4. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Sub-Segmentation Of Primary Anaplastic Large Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous Type
• Systemic Type
• Primary Pulmonary Type
• 6.5. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Sub-Segmentation Of Relapsed Anaplastic Large Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Early Relapse
• Late Relapse

7. Anaplastic Large Cell Lymphoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anaplastic Large Cell Lymphoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anaplastic Large Cell Lymphoma Therapeutics Market

• 8.1. Asia-Pacific Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anaplastic Large Cell Lymphoma Therapeutics Market

• 9.1. China Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 9.2. China Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anaplastic Large Cell Lymphoma Therapeutics Market

• 10.1. India Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anaplastic Large Cell Lymphoma Therapeutics Market

• 11.1. Japan Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 11.2. Japan Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anaplastic Large Cell Lymphoma Therapeutics Market

• 12.1. Australia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anaplastic Large Cell Lymphoma Therapeutics Market

• 13.1. Indonesia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anaplastic Large Cell Lymphoma Therapeutics Market

• 14.1. South Korea Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 14.2. South Korea Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anaplastic Large Cell Lymphoma Therapeutics Market

• 15.1. Western Europe Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 15.2. Western Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anaplastic Large Cell Lymphoma Therapeutics Market

• 16.1. UK Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anaplastic Large Cell Lymphoma Therapeutics Market

• 17.1. Germany Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anaplastic Large Cell Lymphoma Therapeutics Market

• 18.1. France Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anaplastic Large Cell Lymphoma Therapeutics Market

• 19.1. Italy Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anaplastic Large Cell Lymphoma Therapeutics Market

• 20.1. Spain Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anaplastic Large Cell Lymphoma Therapeutics Market

• 21.1. Eastern Europe Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 21.2. Eastern Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anaplastic Large Cell Lymphoma Therapeutics Market

• 22.1. Russia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anaplastic Large Cell Lymphoma Therapeutics Market

• 23.1. North America Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 23.2. North America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anaplastic Large Cell Lymphoma Therapeutics Market

• 24.1. USA Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 24.2. USA Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anaplastic Large Cell Lymphoma Therapeutics Market

• 25.1. Canada Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 25.2. Canada Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anaplastic Large Cell Lymphoma Therapeutics Market

• 26.1. South America Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 26.2. South America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anaplastic Large Cell Lymphoma Therapeutics Market

• 27.1. Brazil Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anaplastic Large Cell Lymphoma Therapeutics Market

• 28.1. Middle East Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 28.2. Middle East Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anaplastic Large Cell Lymphoma Therapeutics Market

• 29.1. Africa Anaplastic Large Cell Lymphoma Therapeutics Market Overview
• 29.2. Africa Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anaplastic Large Cell Lymphoma Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anaplastic Large Cell Lymphoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Anaplastic Large Cell Lymphoma Therapeutics Market Competitive Landscape
• 30.2. Anaplastic Large Cell Lymphoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anaplastic Large Cell Lymphoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Becton, Dickinson and Company
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Genmab A/S
• 31.6. Seagen Inc.
• 31.7. Spectrum Pharmaceuticals Inc.
• 31.8. Kyowa Kirin Co. Ltd.
• 31.9. Kite Pharma
• 31.10. MEI Pharma Inc.
• 31.11. Cell Signaling Technology Inc.
• 31.12. Acrotech Biopharma Inc.
• 31.13. Xenothera
• 31.14. Citius Pharmaceuticals Inc.
• 31.15. Seattle Genetics Inc.

32. Global Anaplastic Large Cell Lymphoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anaplastic Large Cell Lymphoma Therapeutics Market

34. Recent Developments In The Anaplastic Large Cell Lymphoma Therapeutics Market

35. Anaplastic Large Cell Lymphoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Anaplastic Large Cell Lymphoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anaplastic Large Cell Lymphoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anaplastic Large Cell Lymphoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료